JNJ-26366821 / J&J - LARVOL DELTA

SF303. Plastic and Maxillofacial Surgery IV (ACS-CLINCON 2025) - "Presentation times are approximate, and titles will be updated as speakers confirm. Please check back for updates."

Surgery

Thrombopoietin mimetic therapy alleviates radiation-induced bone marrow vascular injury in a bone marrow transplant mouse model. (PubMed, Front Oncol) - "To evaluate the impact of the thrombopoietin mimetic drug JNJ-26366821 (TPOm) on BM vascular recovery in mice undergoing myeloablative radiation conditioning followed by BMT...On day 14 post-BMT, the group receiving 1000 µg/Kg TPOm showed significant shifts (p-value < 0.05) in MVD, Ktrans, and VEGFR2 expression from their corresponding control types (TPOm dose 0 µg) towards levels comparable to healthy controls. TPOm intervention augments BM vascular structure and function, which may be important for hematopoietic recovery and bone marrow function in radiation conditioned hematopoietic stem cell transplant patients, in addition to enhancing platelet recovery."

Journal • Preclinical • Bone Marrow Transplantation • Transplantation • KDR

SF303. Surgical Education V: Resources (Global/IE) (ACS-CLINCON 2024) - "Titles will be added as invited speakers confirm their participation. Please check back for updates."

Clinical

Thrombopoietin mimetic stimulates bone marrow vascular and stromal niches to mitigate acute radiation syndrome. (PubMed, Stem Cell Res Ther) - "TPOm interacts with BM vascular and stromal niches to locally support hematopoietic reconstitution and systemically improve survival in mice after TBI. Therefore, this work warrants the development of TPOm as a potent radiation MCM for the treatment of ARS."

Journal • Stroma • CD31 • PECAM1 • PTPRC • VEGFC

The thrombopoietin mimetic JNJ-26366821 reduces the late injury and accelerates the onset of liver recovery after acetaminophen-induced liver injury in mice. (PubMed, Arch Toxicol) - "While pharmacological interventions, such as N-acetylcysteine (NAC) and 4-methylpyrazole (4-MP), prevent injury there are no therapeutics that promote recovery. In contrast, 4MP and NAC treated at 2 h after APAP significantly attenuated all injury parameters at 24 h but failed to enhance hepatocyte proliferation. Thus, TPOm arrests the progression of liver injury by 24 h after APAP and accelerates the onset of the proliferative response which is essential for liver recovery."

Journal • Preclinical • Hepatology • Liver Failure • PCNA

SF303. Surgical Education V: Surgical Skills (ACS-CLINCON 2023) - "DESCRIPTION All presentation times are approximate."

Oncology

PEGylated thrombopoietin mimetic, JNJ‑26366821 a novel prophylactic radiation countermeasure for acute radiation injury. (PubMed, Sci Rep) - "The drug also increased bone marrow cellularity and megakaryocytes, accelerated multi-lineage hematopoietic recovery, and alleviated radiation-induced soluble markers of bone marrow aplasia and endothelial damage. These results indicate that JNJ‑26366821 is a promising prophylactic radiation countermeasure for hematopoietic acute radiation syndrome with a broad window for medical management in a radiological or nuclear event."

Journal • Aplastic Anemia • Hematological Disorders • Neutropenia • Thrombocytopenia

SF303. Surgical Education V (ACS-CLINCON 2022) - No abstract available

Mitigation of total body irradiation-induced mortality and hematopoietic injury of mice by a thrombopoietin mimetic (JNJ-26366821). (PubMed, Sci Rep) - "Probit analysis of survival in the JNJ-26366821- and saline-treated cohorts revealed a dose reduction factor of 1.113 and significant increases in survival for up to 6 months following irradiation. These results support the potential use of JNJ-26366821 as a medical countermeasure for treatment of acute TBI exposure in case of a radiological/nuclear event when administered from 4 to 24 h post-TBI."

Journal • Preclinical • Hematological Disorders • Thrombocytopenia

The thrombopoietin mimetic JNJ-26366821 increases megakaryopoiesis without affecting malignant myeloid proliferation. (PubMed, Leuk Lymphoma) - "Furthermore, JNJ-26366821 did not enhance in-vivo engraftment of leukemic cells in an AML xenotransplantation murine model. Our results show that JNJ-26366821 stimulates megakaryopoiesis without causing proliferation of the malignant myeloid clones in MDS/AML and provides the rationale for clinical testing of JNJ-26366821 in myeloid malignancies."

Journal • Acute Myelogenous Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology • Thrombocytopenia

A Study of a Single Subcutaneous Dose of JNJ-26366821 in Healthy Participants (clinicaltrials.gov) - P1; N=33; Completed; Sponsor: Janssen Research & Development, LLC; Recruiting ➔ Completed

Clinical • Trial completion

A Study of a Single Subcutaneous Dose of JNJ-26366821 in Healthy Participants (clinicaltrials.gov) - P1; N=36; Recruiting; Sponsor: Janssen Research & Development, LLC; N=24 ➔ 36; Trial completion date: Nov 2019 ➔ Mar 2020

Enrollment change • Trial completion date

Clarifying the relative impacts of vascular and nerve injury that culminate in erectile dysfunction in a pilot study using a rat model of prostate irradiation and a thrombopoietin mimetic. (PubMed, Int J Radiat Oncol Biol Phys) - "These data suggest that vascular protection alone is not sufficient to prevent RI-ED and that cavernous nerve injury plays a key role in RI-ED. Further research is required to delineate the multifactorial nature of RI-ED."

Journal

A Study of a Single Subcutaneous Dose of JNJ-26366821 in Healthy Participants (clinicaltrials.gov) - P1; N=24; Recruiting; Sponsor: Janssen Research & Development, LLC; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open